Faculty of Pharmacy, Integral University, Lucknow, India.
Drug Res (Stuttg). 2021 Oct;71(8):417-428. doi: 10.1055/a-1518-6606. Epub 2021 Jun 22.
Prostate carcinoma is typical cancer. It is the second most common cancer globally. The estimated new cases in 2020 was 191 930 and estimated deaths was 33 330. Age, family history, & genetic factors are major factors that drive prostate cancer. Although, for treating metastatic disease, the major therapies available are radiation,bisphosphonate, and palliative chemotherapy. But the major drawback is therapy is disease-driven and later becomes metastatic and requires treatment. The ability to revolutionize cancer treatment by major targeting vehicles via the exploration of nanoemulsion suggests a potential for cancer treatment. The unique property of a biphasic liquid dosage form called nanoemulsion to reach leaky tumor vasculature is due to its nano-meter oil-droplet size of 20-200 nm. Recent reporting on nanoemulsions disclose their embracing and lay alternative for re-purposing herbal and synthetic drugs and their combination especially for targeting prostate cancer formulating an obtainable nanomedicine. So, this article emphasizes the use of nanoemulsions incorporating therapeutic agents for successful and targeted delivery for prostate cancer.
前列腺癌是一种典型的癌症。它是全球第二大常见癌症。据估计，2020 年的新发病例为 191930 例，死亡病例为 33330 例。年龄、家族史和遗传因素是导致前列腺癌的主要因素。尽管如此，对于转移性疾病的治疗，主要可用的疗法是放射治疗、双膦酸盐和姑息性化疗。但主要的缺点是治疗是针对疾病的，然后会变成转移性的，需要治疗。通过探索纳米乳液，利用主要靶向载体来彻底改变癌症治疗的能力表明了癌症治疗的一种潜力。这种被称为纳米乳液的双相液体剂型具有到达渗漏性肿瘤血管系统的独特特性，这要归功于其 20-200nm 的纳米级油滴大小。最近关于纳米乳液的报告揭示了它们对重新利用草药和合成药物及其组合的接受和替代，特别是对于前列腺癌的靶向制剂，形成了一种可行的纳米医学。因此，本文强调了使用纳米乳液将治疗剂成功靶向递送到前列腺癌的用途。
